Taken together, our study suggests that combined treatment with JAK3 and MDM2 inhibitors may potentially increase the drug benefit for T-ALL patients with PHF6 and JAK3 comutation. The gene discussed is PHF6; the disease is acute lymphoblastic leukemia.